150 related articles for article (PubMed ID: 21208168)
1. Recent topics on pharmacotherapy for amphetamine-type stimulants abuse and dependence.
Chen H; Wu J; Zhang J; Hashimoto K
Curr Drug Abuse Rev; 2010 Dec; 3(4):222-38. PubMed ID: 21208168
[TBL] [Abstract][Full Text] [Related]
2. Treatment of methamphetamine use disorders: an update.
Rawson RA; Gonzales R; Brethen P
J Subst Abuse Treat; 2002 Sep; 23(2):145-50. PubMed ID: 12220612
[TBL] [Abstract][Full Text] [Related]
3. Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China.
Zhang Y; Lu C; Zhang J; Hu L; Song H; Li J; Kang L
Addict Behav; 2013 Jan; 38(1):1424-30. PubMed ID: 23006246
[TBL] [Abstract][Full Text] [Related]
4. Treatments for methamphetamine abuse: a literature review for the clinician.
Brackins T; Brahm NC; Kissack JC
J Pharm Pract; 2011 Dec; 24(6):541-50. PubMed ID: 22095579
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of amphetamine-type stimulant dependence: an update.
Brensilver M; Heinzerling KG; Shoptaw S
Drug Alcohol Rev; 2013 Sep; 32(5):449-60. PubMed ID: 23617468
[TBL] [Abstract][Full Text] [Related]
6. Overview of amphetamine-type stimulant mortality data--UK, 1997-2007.
Schifano F; Corkery J; Naidoo V; Oyefeso A; Ghodse H
Neuropsychobiology; 2010; 61(3):122-30. PubMed ID: 20110737
[TBL] [Abstract][Full Text] [Related]
7. Current and Emerging Treatments for Methamphetamine Use Disorder.
Moszczynska A
Curr Neuropharmacol; 2021; 19(12):2077-2091. PubMed ID: 34344291
[TBL] [Abstract][Full Text] [Related]
8. Advances and challenges in pharmacotherapeutics for amphetamine-type stimulants addiction.
Cao DN; Shi JJ; Hao W; Wu N; Li J
Eur J Pharmacol; 2016 Jun; 780():129-35. PubMed ID: 27018393
[TBL] [Abstract][Full Text] [Related]
9. Clinical neuroscience of amphetamine-type stimulants: From basic science to treatment development.
Courtney KE; Ray LA
Prog Brain Res; 2016; 223():295-310. PubMed ID: 26806782
[TBL] [Abstract][Full Text] [Related]
10. Approaches to the development of medications for the treatment of methamphetamine dependence.
Vocci FJ; Appel NM
Addiction; 2007 Apr; 102 Suppl 1():96-106. PubMed ID: 17493058
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological approaches to methamphetamine dependence: a focused review.
Karila L; Weinstein A; Aubin HJ; Benyamina A; Reynaud M; Batki SL
Br J Clin Pharmacol; 2010 Jun; 69(6):578-92. PubMed ID: 20565449
[TBL] [Abstract][Full Text] [Related]
12. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms.
Moratalla R; Khairnar A; Simola N; Granado N; García-Montes JR; Porceddu PF; Tizabi Y; Costa G; Morelli M
Prog Neurobiol; 2017 Aug; 155():149-170. PubMed ID: 26455459
[TBL] [Abstract][Full Text] [Related]
13. A case of methamphetamine use disorder treated with the antibiotic drug minocycline.
Tanibuchi Y; Shimagami M; Fukami G; Sekine Y; Iyo M; Hashimoto K
Gen Hosp Psychiatry; 2010; 32(5):559.e1-3. PubMed ID: 20851278
[TBL] [Abstract][Full Text] [Related]
14. Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students.
Brière FN; Fallu JS; Janosz M; Pagani LS
J Epidemiol Community Health; 2012 Nov; 66(11):990-4. PubMed ID: 22516739
[TBL] [Abstract][Full Text] [Related]
15. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.
Baumann MH; Phillips JM; Ayestas MA; Ali SF; Rice KC; Rothman RB
Ann N Y Acad Sci; 2002 Jun; 965():92-108. PubMed ID: 12105088
[TBL] [Abstract][Full Text] [Related]
17. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis.
Ujike H; Sato M
Ann N Y Acad Sci; 2004 Oct; 1025():279-87. PubMed ID: 15542728
[TBL] [Abstract][Full Text] [Related]
18. Meth/amphetamine use and associated HIV: Implications for global policy and public health.
Degenhardt L; Mathers B; Guarinieri M; Panda S; Phillips B; Strathdee SA; Tyndall M; Wiessing L; Wodak A; Howard J;
Int J Drug Policy; 2010 Sep; 21(5):347-58. PubMed ID: 20117923
[TBL] [Abstract][Full Text] [Related]
19. The neurotoxicity of amphetamines during the adolescent period.
Teixeira-Gomes A; Costa VM; Feio-Azevedo R; Bastos Mde L; Carvalho F; Capela JP
Int J Dev Neurosci; 2015 Apr; 41():44-62. PubMed ID: 25482046
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of psychostimulant drugs for amphetamine abuse or dependence.
Pérez-Mañá C; Castells X; Torrens M; Capellà D; Farre M
Cochrane Database Syst Rev; 2013 Sep; (9):CD009695. PubMed ID: 23996457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
